Business Wire

GCCA

30.3.2022 08:02:04 CEST | Business Wire | Press release

Share
GCCA: Cement and Concrete Industry Launches Net Zero Accelerators Across the World – Including Focus on the ‘Global South’

The Global Cement and Concrete Association (GCCA) has today launched a series of Net Zero Accelerator initiatives to help national cement and concrete industries decarbonise in line with the GCCA’s 2050 Net Zero Global Industry Roadmap.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220329005500/en/

The first wave of Accelerators will launch in Egypt, which later this year will be the host country for COP27, as well as in India, Thailand and Colombia. These countries combined represent approximately 10% of global cement and concrete production. Concrete, a local and durable material, is fundamental to overcoming sustainable development challenges which many parts of the world are facing, such as population growth, increasing urbanisation and the need for more resilient infrastructure and communities in the face of a rapidly changing climate.

Globally, cement and concrete manufacture accounts for around 7% of CO2 emissions. The global plan to eliminate these emissions by 2050 requires all parts of the world to accelerate the reductions in CO2 emissions. The Accelerator program will identify the barriers to decarbonisation in target countries and recommend key actions. This includes encouraging government policies that can have an immediate impact, such as better recycling, the use of waste as an alternative to fossil fuels, and other circular economy practices. It will also include identifying lighthouse projects that can fully eliminate emissions over the next decades, such as carbon capture utilisation and storage technologies.

Thomas Guillot, GCCA Chief Executive, said: “Last year our industry made a breakthrough net zero global commitment. This is the next logical step as we move our focus from a global roadmap to driving decisive local action.

“Concrete will continue to be the world’s most used building material for decades to come, meaning global cooperation between governments and industry is crucial to ensuring net zero targets are met. Our Net Zero Accelerators will offer collaboration and support to a number of target countries to help them decarbonise and align with the global roadmap. I’m proud to launch the first phase of the Accelerator program to assist these nations in embracing greener technologies and work towards a more sustainable future together. I now call on more partners around the world to join us and be part of this movement.”

His Excellency, Dr Mahmoud Mohieldin, COP 27 UNFCCC High-Level Champion of Egypt, said: “Much of the infrastructure the world needs to overcome our major global challenges – such as alleviating poverty, the need for clean water and energy, and safe, affordable housing – is yet to be built.

“Cement and concrete will play a critical role in delivering a healthier, more resilient, zero carbon world as the industry moves to rapidly and fully decarbonise. As such, we are pleased to support the Net Zero Accelerator initiative, helping developing countries achieve their decarbonisation targets, as we work to support all industries and countries with their climate ambitions to help build a more sustainable future for all. The full and willing participation of a sector which accounts for 7-8% of global CO2 emissions is critical to contribute to the goal of the 2015 Paris Climate Change Agreement to limit global warming well below 2°C degrees and as close as possible to 1.5°C.”

The accelerator programme comprises three elements – i. net zero national roadmaps including emissions forecasts, reduction levers, policy needs and the industry commitment; ii. identification and funding exploration for large scale carbon cutting ‘Lighthouse’ Projects; and iii. policy dialogues with national governments to help accelerate the transition.

The GCCA is partnering with the cement and concrete industry on the ground and will work closely with policymakers, designers, and the construction sector to help overcome procurement and resourcing challenges, as well as demonstrate the business case for greener technologies to be used on a wider scale.

The Accelerators will help align Phase 1 countries’ cement and concrete industries with the GCCA’s 2050 Net Zero Roadmap , which marked the biggest global commitment by a heavy industry to decarbonise when it was launched last year. The Roadmap sets out a path to fully decarbonise by 2050, a target aligned with the Paris Agreement to limit global warming to 1.5°C. The roadmap actions between now and 2030, to reduce concrete related emissions by 25%, will prevent almost 5 billion tonnes of carbon from entering the atmosphere compared to a business-as-usual scenario.

Lighthouse Projects and a new tranche of phase two Accelerators will be announced later this year.

-ends-

Notes to editors:

About the GCCA:

Launched in January 2018, the Global Cement and Concrete Association (GCCA) is dedicated to developing and strengthening the sector’s contribution to sustainable construction. The GCCA aims to foster innovation throughout the construction value chain in collaboration with industry associations as well as architects, engineers, and innovators. In this way, the association demonstrates how concrete solutions can meet global construction challenges and sustainable development goals while showcasing responsible industrial leadership in the manufacture and use of cement and concrete. The GCCA is headquartered in London, England. It complements and supports the work done by associations at the national and regional levels.

The GCCA works with key a range of partners. It co-leads the Mission Possible Partnership’s Concrete Action for Climate initiate with the World Economic Forum. The GCCA is also an official accelerator for the Race to Zero.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye